COVID-19 Vaccine Authorized in India-A Mini Review

Abstract

Novel Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), which is responsible for Coronavirus disease (COVID-19) has spread to 220 countries and has been found to be challenging. Many variants detected after Wuhan-Hu-1 reference which were able to develop the resistance against the neutralizing antibodies induced by vaccine and may cause false negative results in diagnostic tests targeting the S gene. The COVID-19 cases are increasing rapidly in India and the government authorized a new vaccine for restricted use in emergency situation. This review discusses about the efficacy, safety, and economical aspects of vaccines authorized in India. The rAd26-s & rAd5-s (Gamaleya Research Institute of Epidemiology and Microbiology) demonstrate high efficacy as well as safety, followed by BBV152 (Bharat Biotech) and AZD1222 (Oxford AstraZeneca); AZD1222 is more economical than other two.

Note:
Funding Statement: There is no funding from any institution.

Declaration of Interests: There are no competing interests from any of the authors.

Keywords: COVID-19, SARS-CoV-2, Immunization, Vaccine, Efficacy

JEL Classification: i